New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval
Health technology assessment body NICE has also issued guidances rejecting three products.
You may also be interested in...
The SMC, Scotland’s health technology appraisal body, wants more data for Albireo Pharma’s ultra-orphan Bylvay and Novartis’s rare disease drug Adakveo.
Treatments for obesity, chronic kidney disease, advanced endometrial cancer and acute myeloid leukemia have been given the thumbs up from the health technology assessment body, NICE.
Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.